Andrew Farquarson, Director, Technology Transfer, has been a member of the EU Commission’s Expert Group appointed in 2012 to advise on the Biotech Directive and patent protection for biotech/genetic engineering inventions.
Their report has now been published.
Medical related information are on page 127 (are/should stem cells, including human embryonic stem cells, be patentable ) and page 176 (should patents on nucleic acids be use-limited).
Related stories
LifeArc backs new report that warns UK business R&D investment has ‘stagnated’ and calls for improved investment incentives
Read more: LifeArc backs new report that warns UK business R&D investment has ‘stagnated’ and calls for improved investment incentives
Kickstart drug repurposing: smashing the roadblocks on the route to patients
Read more: Kickstart drug repurposing: smashing the roadblocks on the route to patients
Advanced diagnosis for patients with rare conditions
Read more: Advanced diagnosis for patients with rare conditions